Kanagawa, Japan, 6 March 2019 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Yusuke Tominari, Ph.D., Chief Executive Officer and Chief Scientific Officer of FIMECS, will make a presentation at The European Protein Degradation Congress (22-23 May 2019 Basel, Switzerland).
Title is “Efficient discovery platform of the targeted protein degrader drugs”. In this presentation, RaPPIDS™ platform will be introduced based on a case study, IRAK-M degrader program.
For more information:
https://kisacoresearch.com/events/european-protein-degradation-congress#why-attend
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
About RaPPIDS™
RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders.
# # #
FIMECS, Inc. Media and Investor Contact:
Yusuke Kohno, CFO and VP of corporate development
TEL: +81-50-5328-9458
E-mail: info@fimecs.com